Related references
Note: Only part of the references are listed.Mutual pharmacokinetic interactions between steady-state bosentan and sildenafil
Gary Burgess et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Experience with inhaled iloprost and bosentan in portopulmonary hypertension
M. M. Hoeper et al.
EUROPEAN RESPIRATORY JOURNAL (2007)
Selective endothelinA receptor antagonism with sitaxsentan for pulmonary arterial hypertension associated with connective tissue disease
Reda E. Girgis et al.
ANNALS OF THE RHEUMATIC DISEASES (2007)
Results of European post-marketing surveillance of bosentan in pulmonary hypertension
M. Humbert et al.
EUROPEAN RESPIRATORY JOURNAL (2007)
A meta-analysis of trials of pulmonary hypertension: A clinical condition looking for drugs and research methodology
Alejandro Macchia et al.
AMERICAN HEART JOURNAL (2007)
Effect of bosentan on plasma endothelin-1 concentration in patients with pulmonary arterial hypertension
Yoshimune Hiramoto et al.
CIRCULATION JOURNAL (2007)
Sitaxsentan treatment for patients with pulmonary arterial hypertension discontinuing bosentan
Raymond L. Benza et al.
JOURNAL OF HEART AND LUNG TRANSPLANTATION (2007)
Sitaxsentan: a selective endothelin-A receptor antagonist, for the treatment of pulmonary arterial hypertension
Robyn J. Barst
EXPERT OPINION ON PHARMACOTHERAPY (2007)
Endothelin-1-induced pulmonary vasoreactivity is regulated by ETA and ETB receptor interactions
Stephanie Sauvageau et al.
JOURNAL OF VASCULAR RESEARCH (2007)
Effects of bosentan, an endothelin receptor antagonist, on bile salt export pump and multidrug resistance-associated protein 2
Yuji Mano et al.
BIOPHARMACEUTICS & DRUG DISPOSITION (2007)
ARIES-1: A placebo-controlled, efficacy and safety study of ambrisentan in patients with pulmonary arterial hypertension
Ronald J. Oudiz et al.
CHEST (2006)
Ambrisentan rescue therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function abnormalities
Michael D. McGoon et al.
CHEST (2006)
Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions
C. P. Denton et al.
ANNALS OF THE RHEUMATIC DISEASES (2006)
Dual ETA/ETB vs. selective ETA endothelin receptor antagonism in patients with pulmonary hypertension
C. F. Opitz et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2006)
Bosentan therapy in patients with Eisenmenger syndrome - A multicenter, double-blind, randomized, placebo-controlled study
Nazzareno Galie et al.
CIRCULATION (2006)
Systemic sclerosis associated pulmonary hypertension: improved survival in the current era
M. H. Williams et al.
HEART (2006)
Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan
Robyn J. Barst et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2006)
Ambrisentan, a non-peptide endothelin receptor antagonist
Hartmut Vatter et al.
CARDIOVASCULAR DRUG REVIEWS (2006)
Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension
S Provencher et al.
EUROPEAN HEART JOURNAL (2006)
Etiology-specific endothelin-1 clearance in human precapillary pulmonary hypertension
D Langleben et al.
CHEST (2006)
Ambrisentan therapy for pulmonary arterial hypertension
N Galié et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2005)
Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension
GA Paul et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2005)
The 6-min walk test (6MW) as an efficacy endpoint in pulmonary arterial hypertension clinical trials: Demonstration of a ceiling effect
AE Frost et al.
VASCULAR PHARMACOLOGY (2005)
Endothelin-1 enhances oxidative stress, cell proliferation and reduces apoptosis in human umbilical vein endothelial cells:: role of ETB receptor, NADPH oxidase and caveolin-1
F Dong et al.
BRITISH JOURNAL OF PHARMACOLOGY (2005)
Survival with first-line bosentan in patients with primary pulmonary hypertension
VV McLaughlin et al.
EUROPEAN RESPIRATORY JOURNAL (2005)
Role of endothelin in fibrosis and anti-fibrotic potential of bosentan
M Clozel et al.
ANNALS OF MEDICINE (2005)
Endothelin-A receptor antagonism reduces blood pressure and increases renal blood flow in hypertensive patients with chronic renal failure - A comparison of selective and combined endothelin receptor blockade
J Goddard et al.
CIRCULATION (2004)
Sitaxsentan therapy for pulmonary arterial hypertension
RJ Barst et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2004)
Drug therapy: Treatment of pulmonary arterial hypertension
M Humbert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension
O Sitbon et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2004)
Guidelines on diagnosis and treatment of pulmonary arterial hypertension -: The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology
N Galiè et al.
EUROPEAN HEART JOURNAL (2004)
End points and clinical trial designs in pulmonary arterial hypertension - Clinical and regulatory perspectives
MM Hoeper et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2004)
Endothelin-1 promotes myofibroblast induction through the ETA receptor via a rac/phosphoinositide 3-kinase/akt-dependent pathway and is essential for the enhanced contractile phenotype of fibrotic fibroblasts
SW Xu et al.
MOLECULAR BIOLOGY OF THE CELL (2004)
Fluorescence resonance energy transfer analysis reveals the existence of endothelin-A and endothelin-B receptor homodimers
B Gregan et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2004)
Mechanisms of disease: Pulmonary arterial hypertension
HW Farber et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Novel benzo[1,4]diazepin-2-one derivatives as endothelin receptor antagonists
MH Bolli et al.
JOURNAL OF MEDICINAL CHEMISTRY (2004)
Sustained symptomatic, functional, and hemodynamic benefit with the selective endothelin-A receptor antagonist, sitaxsentan, in patients with pulmonary arterial hypertension - A 1-year follow-up study
D Langleben et al.
CHEST (2004)
Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension
RJ Barst et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2003)
Cardiac fibrosis occurs early and involves endothelin and AT-1 receptors in hypertension due to endogenous angiotensin II
TM Seccia et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2003)
Angiotensin II type 1 and endothelin type A receptor antagonists modulate the extracellular matrix regulatory system differently in diastolic heart failure
J Yoshida et al.
JOURNAL OF HYPERTENSION (2003)
Effects of bosentan on cellular processes involved in pulmonary arterial hypertension: do they explain the long-term benefit?
M Clozel
ANNALS OF MEDICINE (2003)
Bosentan therapy for pulmonary arterial hypertension
LJ Rubin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
ETA and ETB receptors modulate the proliferation of human pulmonary artery smooth muscle cells
N Davie et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2002)
Endothelin-1 stimulates human colonic myofibroblast contraction and migration
LE Kernochan et al.
GUT (2002)
Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension
C Rubens et al.
CHEST (2001)
Are selective endothelin A receptor antagonists better than mixed antagonists?
A Bagnall et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2001)
The heart and pulmonary vasculature in scleroderma: clinical features and pathobiology
JG Coghlan et al.
CURRENT OPINION IN RHEUMATOLOGY (2001)
Simultaneous blockade of endothelin A and B receptors in ischemic acute renal failure is detrimental to long-term kidney function
JM Forbes et al.
KIDNEY INTERNATIONAL (2001)
The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: A potential mechanism for hepatic adverse reactions
K Fattinger et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2001)
Fibroblast matrix gene expression and connective tissue remodeling: Role of endothelin-1
SW Xu et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2001)
Regression of renal vascular fibrosis by endothelin receptor antagonism
JJ Boffa et al.
HYPERTENSION (2001)
Endothelin receptor antagonism in patients with chronic heart failure
MP Love et al.
CARDIOVASCULAR RESEARCH (2000)
Pulmonary fibrosis and chronic lung inflammation in ET-1 transgenic mice
B Hocher et al.
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY (2000)
Acute endothelin A receptor blockade causes selective pulmonary vasodilation in patients with chronic heart failure
MM Givertz et al.
CIRCULATION (2000)
Endothelin mediates pulmonary vascular remodelling in a canine model of chronic embolic pulmonary hypertension
H Kim et al.
EUROPEAN RESPIRATORY JOURNAL (2000)
Attenuation of pulmonary vascular hypertension and cardiac hypertrophy with sitaxsentan sodium, an orally active ETA receptor antagonist
RG Tilton et al.
PULMONARY PHARMACOLOGY & THERAPEUTICS (2000)
Share Paper
